)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
EKF Diagnostics
EKF Diagnostics (EKF) investor relations material
EKF Diagnostics H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary24 Mar, 2026
Executive summary
Strategy targets leadership in point-of-care hemoglobin and ketone testing by 2029, with transformation of Life Sciences into a contract development and manufacturing organization.
Achieved 3% revenue growth to GBP 51.6 million in 2025, with improved profitability and operational focus.
Expanded commercial teams, completed product portfolio simplification, and initiated capacity increases in Hematology.
Significant progress in U.S. blood bank market, LATAM expansion, and NGO partnerships in Africa.
Share buyback program executed, repurchasing nearly 20 million shares (4.4% of business) for GBP 5 million.
Financial highlights
Revenue increased 3% to GBP 51.6 million compared to 2024.
Gross margin improved to 51% from 48% in 2024.
EBITDA reached GBP 12.4 million, meeting targets.
Cash at year-end was GBP 15.8 million after GBP 5 million spent on buybacks.
Profit before tax improved; higher tax charge due to German tax provisions.
Outlook and guidance
2026 objectives focus on commercial development in strategic markets, operational excellence, and CapEx investment.
Scheduled product launches in 2027 and 2028, with continued investment in R&D and new product development.
Life Sciences strategy realignment and relaunch as a value-enhancing CDMO planned for 2026.
Double-digit BHB growth in the U.S. expected to continue.
Life Sciences fermentation capacity and revenue
German tax provision and recovery timeline
BCA agreement impact on U.S. blood bank growth
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from EKF Diagnostics
- Revenue up 3% and adjusted EBITDA up 10% in FY 2025, with strong cash and margin gains.EKF
Q4 2025 TU27 Jan 2026 - Gross margin rose to 48% as focus shifts to high-growth Hematology and BHB segments.EKFH2 202426 Dec 2025
- Gross margin rose to 50.2% and EBITDA increased 7.4%, supporting a positive growth outlook.EKFH1 202516 Sep 2025
- Improved margins and strong cash flow position support FY 2025 growth targets.EKFTrading Update28 Jul 2025
- Gross margin and EBITDA rose despite lower revenue, with a positive full-year outlook.EKFH1 202413 Jun 2025
- Strong H1 2024 EBITDA growth and cash generation position EKF for continued improvement.EKFTrading Update13 Jun 2025
- Gross margin and EBITDA rise as EKF shifts to higher margin products and strengthens cash.EKFTrading Update6 Jun 2025
Next EKF Diagnostics earnings date
H1 202625 Sep, 2026
EKF Diagnostics
Next EKF Diagnostics earnings date
H1 202625 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage